Indivior Pharmaceuticals (INDV) Cash & Equivalents (2021 - 2026)

Indivior Pharmaceuticals' Cash & Equivalents history runs 6 years deep, the most recent figure standing at $175.0 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 52.96% year-over-year to $175.0 million; the TTM figure through Mar 2026 stood at $175.0 million (down 52.96% YoY), while the FY2025 annual figure was $195.0 million, down 38.87% from the prior year.
• Cash & Equivalents was $175.0 million for Q1 2026 at Indivior Pharmaceuticals, down from $195.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $774.0 million in Q4 2022 to a low of $175.0 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $388.2 million across 5 years, with a median of $345.5 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents slumped 59.17% in 2023, then increased 0.95% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $774.0 million in 2022, then plunged by 59.17% to $316.0 million in 2023, then gained by 0.95% to $319.0 million in 2024, then slumped by 38.87% to $195.0 million in 2025, then dropped by 10.26% to $175.0 million in 2026.
• The last three Cash & Equivalents figures came in at $175.0 million (Q1 2026), $195.0 million (Q4 2025), and $445.0 million (Q3 2025), per Business Quant data.